In 2019, the largest genetic study of depression ever conducted — 807,553 individuals, 246,363 of them with depression — pointed to a single gene more strongly than any other: SORCS3¹¹ SORCS3
Sortilin-related VPS10 domain-containing receptor 3 — a member of the VPS10 family of sorting receptors, which guide cargo proteins between cellular compartments in neurons. SORCS3 is expressed predominantly in the brain, where it localizes to the postsynaptic density of glutamatergic synapses. The rs10786831 variant lies within an intron of SORCS3, in a position that likely influences gene expression rather than protein structure. The G allele at this position is the risk-associated configuration for major depressive disorder, identified with high confidence across multiple independent cohorts.

The Mechanism

SORCS3 is a VPS10-domain receptor²² VPS10-domain receptor
The vacuolar protein sorting 10 (VPS10) domain family sorts cargo between cellular compartments. Members include SORTILIN, SORCS1, SORCS2, and SORCS3. In neurons, these receptors are critical for controlling which proteins reach the synapse, and at what concentrations. that localizes to the postsynaptic density — the dense protein scaffold that anchors neurotransmitter receptors directly opposite the presynaptic terminal. Its primary job at glutamatergic synapses is to regulate the surface availability of [AMPA receptors | AMPA receptors (AMPARs) are the main mediators of fast excitatory neurotransmission. Their density at the synapse determines how strongly a neuron responds to incoming glutamate signals. Regulated insertion and removal of AMPARs from the postsynaptic membrane is the core mechanism of synaptic plasticity — the cellular basis of learning and memory.], the fast-excitatory receptors that control the amplitude of synaptic responses.

SORCS3 interacts with PICK1³³ PICK1
Protein interacting with C-kinase 1 — an adaptor protein that mediates AMPA receptor internalization from the postsynaptic membrane. PICK1-SORCS3 interaction is required for normal long-term synaptic depression (LTD), the process of weakening synaptic connections that underlies memory updating and fear extinction. to orchestrate AMPA receptor internalization. When SORCS3 is absent or reduced in function, PICK1 cannot reach the postsynaptic density properly, AMPA receptors become more mobile and exchange more rapidly at the synapse, and the normal form of synaptic depression is impaired. In parallel, SORCS3 and its relative SORCS1 function as intracellular trafficking receptors for TrkB⁴⁴ intracellular trafficking receptors for TrkB
TrkB (tropomyosin-related kinase B) is the primary receptor for brain-derived neurotrophic factor (BDNF). When SORCS3 routes TrkB away from the cell surface, it attenuates BDNF signaling. Loss of SORCS3 leaves TrkB unrestrained, potentially dysregulating the neurotrophin response. — meaning SORCS3 shapes both glutamate receptor dynamics and neurotrophin-receptor signaling simultaneously.

The Evidence

The depression association for rs10786831 rests on two large independent signals. The Hyde et al. 2016 study⁵⁵ Hyde et al. 2016 study
Identification of 15 genetic loci associated with risk of major depression in individuals of European descent. Nature Genetics 2016. using 23andMe data (N > 307,000) identified the G allele as the risk configuration (beta = −0.0297, p = 8×10⁻⁹ for the liability scale). The signal was replicated in the Howard et al. 2019 meta-analysis⁶⁶ Howard et al. 2019 meta-analysis
Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nature Neuroscience, 2019. covering 807,553 participants, which elevated SORCS3 to the most significant novel gene in the study, with the locus surviving replication in 1,306,354 additional individuals (87 of 102 variants replicated).

The functional evidence from animal models reinforces the genetic signal: SORCS3-knockout mice⁷⁷ SORCS3-knockout mice
Breiderhoff et al. 2013 — PLoS One; SORCS3-deficient mice show accelerated fear extinction and impaired spatial memory (Barnes maze), while locomotion and initial fear acquisition remain normal. The defect was traced to disrupted PICK1 localization at the postsynaptic density. display accelerated extinction of fear memory — they lose conditioned fear responses far faster than wild-type controls — and exhibit spatial learning deficits consistent with hippocampal LTD impairment. Electrophysiological recordings from knockout hippocampal slices show a 33% reduction in CA1 synaptic transmission⁸⁸ 33% reduction in CA1 synaptic transmission
Christiansen et al. 2017 — Hippocampus; SorCS3 knockout mice aged P55-65 showed 33% reduction in field EPSPs at CA1 Schaffer collaterals, with enhanced AMPA receptor mobility at the postsynaptic density. and enhanced AMPA receptor mobility at the postsynaptic density in adult mice — a pattern consistent with impaired ability to consolidate and update emotional memories.

The same rs10786831-A allele (the opposite configuration) is independently associated with insomnia⁹⁹ insomnia
Watanabe et al. 2022 — Nature Genetics; GWAS of 2.3M individuals identified 554 insomnia loci; rs10786831-A reached p=2×10⁻¹³ (beta=0.007 increase). at p = 2×10⁻¹³ in a separate GWAS of 2.3 million individuals. This pleiotropic pattern — opposite alleles tagging different disorders — reflects the complex regulatory role of this locus in arousal and emotional memory circuits.

Practical Actions

The actionable insight for G allele carriers centers on supporting synaptic plasticity mechanisms that SORCS3 would normally facilitate: glutamate receptor trafficking, fear extinction circuitry, and neurotrophin signaling. The most evidence-backed behavioral intervention for hippocampal AMPA receptor insertion and LTP induction is aerobic exercise, which also robustly increases hippocampal BDNF. Omega-3 DHA is incorporated into postsynaptic neuronal membranes and is required for optimal AMPA receptor conformation and TrkB signaling. Magnesium is a required cofactor for NMDA receptor function and BDNF synthesis pathways — deficiency amplifies stress reactivity and impairs the very LTD/LTP balance that SORCS3 normally helps calibrate.

Interactions

rs10786831 and the neighboring rs11599236 both lie within SORCS3 intronic regions but tag different GWAS signals — rs11599236 is primarily associated with mood instability, neuroticism, and cross-disorder psychiatric risk, while rs10786831 is the depression-specific lead. Individuals carrying risk alleles at both loci may have compounded effects on neurotrophin trafficking and synaptic depression mechanisms. SORCS3 interacts epistatically with SORCS1 and SORCS2 in the VPS10 receptor family — variants in SORCS1 (rs600879) have been associated with Alzheimer's risk and may compound SORCS3 effects on TrkB trafficking. The SORCS3 gene-set overlaps substantially with synaptic pathways implicated by schizophrenia and bipolar GWAS, making rs10786831 a pleiotropic node at the intersection of depression, fear circuitry, and cognitive plasticity.

The MTNR1B gene encodes melatonin receptor 1B¹¹ melatonin receptor 1B
One of two G-protein-coupled receptors for melatonin (MT1 and MT2). MT2 (MTNR1B) is expressed in the brain, retina, and — critically — in pancreatic beta cells (MT2), a receptor found not only in the brain but also on the insulin-producing beta cells of the pancreas. This dual role places MTNR1B at the crossroads of two fundamental biological systems: the circadian clock and glucose metabolism.

The rs10830963 variant sits in an intron of MTNR1B and is one of the strongest GWAS²² GWAS
Genome-wide association study: an approach that scans the entire genome of thousands of people to find genetic variants associated with a trait or disease hits for fasting glucose levels ever identified, reaching a significance of P = 3.2 x 10^-50 in the original discovery. The G allele — carried by roughly 28% of Europeans and up to 45% of East Asians — extends the duration of melatonin signaling in pancreatic beta cells, impairing their ability to release insulin in response to glucose. This makes it one of the most actionable chrono-nutrition³³ chrono-nutrition
The study of how the timing of food intake interacts with circadian biology to affect metabolic health SNPs: for G carriers, when you eat may matter as much as what you eat.

The Mechanism

Melatonin is the hormone of darkness — it rises in the evening, peaks during the night, and falls before dawn. When melatonin binds MT2 receptors on pancreatic beta cells, it activates inhibitory G-proteins⁴⁴ inhibitory G-proteins
Gi proteins that reduce intracellular cAMP levels, dampening the cell's ability to secrete insulin in response to glucose (Gi), reducing cAMP and suppressing glucose-stimulated insulin secretion. This is normally useful: it prevents insulin surges during sleep when you are not eating.

The rs10830963 G allele increases MTNR1B expression in beta cells. More MT2 receptors mean stronger melatonin-mediated suppression of insulin secretion, and Lane and colleagues⁵⁵ Lane and colleagues
Lane JM et al. Impact of Common Diabetes Risk Variant in MTNR1B on Sleep, Circadian, and Melatonin Physiology. Diabetes, 2016 showed that G carriers also have a 41-minute longer duration of elevated melatonin and a 1.37-hour delayed melatonin offset in the morning. The result is a wider window during which insulin secretion is suppressed — a window that overlaps with meal times if you eat late at night or early in the morning.

The Evidence

The original GWAS discovery⁶⁶ original GWAS discovery
Prokopenko I et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet, 2009 across 36,610 individuals found each G allele raises fasting glucose by 0.07 mmol/L (P = 3.2 x 10^-50). A simultaneous study by Lyssenko and colleagues⁷⁷ Lyssenko and colleagues
Lyssenko V et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet, 2009 confirmed that the risk genotype impairs early insulin response to both oral and intravenous glucose, with MTNR1B expression elevated in islets of risk carriers.

A large replication study⁸⁸ large replication study
Sparsø T et al. G-allele of intronic rs10830963 in MTNR1B confers increased risk of impaired fasting glycemia and type 2 diabetes. Diabetes, 2009 of 19,605 Europeans found the G allele increases impaired fasting glycemia risk with OR 1.64 (P = 5.5 x 10^-11). In the UK Biobank⁹⁹ UK Biobank
Tan X et al. Associations between chronotype, MTNR1B genotype and risk of type 2 diabetes in UK Biobank. J Intern Med, 2020 analysis of 337,083 participants, CG carriers had OR 1.10 and GG carriers OR 1.21 for type 2 diabetes compared to CC.

The meal-timing dimension was demonstrated in a randomized crossover trial¹⁰¹⁰ randomized crossover trial
Garaulet M et al. Late dinner impairs glucose tolerance in MTNR1B risk allele carriers: a randomized, cross-over study. Clin Nutr, 2017: eating late (when melatonin is elevated) significantly impaired glucose tolerance in G carriers but not in CC individuals. A larger follow-up¹¹¹¹ larger follow-up
Lopez-Minguez J et al. Interplay of Dinner Timing and MTNR1B Type 2 Diabetes Risk Variant on Glucose Tolerance and Insulin Secretion. Diabetes Care, 2022 with 845 participants confirmed that late dinner (1 hour before bed vs. 4 hours) produced 3.5-fold higher melatonin levels, 6.7% lower insulin area under the curve, and 8.3% higher glucose AUC — with significantly stronger effects in G carriers.

Practical Implications

This is one of the most actionable SNPs in the glucose-metabolism space because the intervention is simple: eat dinner earlier. For G carriers, the overlap of high melatonin and high glucose from a late meal is what drives the impairment — shifting the last meal to at least 3-4 hours before bedtime substantially reduces this effect.

Morning eating may also matter. Lane et al. found that the T2D risk in G carriers was amplified in early risers, likely because these individuals wake while melatonin is still elevated. Having breakfast 1-2 hours after waking (rather than immediately) may help avoid the melatonin-glucose collision for early-rising G carriers.

Weight management is also relevant: the POUNDS Lost trial¹²¹² POUNDS Lost trial
Huang T et al. A circadian rhythm-related MTNR1B genetic variant modulates the effect of weight-loss diets on changes in adiposity and body composition. Am J Clin Nutr, 2018 found that the G allele modulates the effect of diet composition on weight loss, with G carriers losing more weight on low-fat diets and gaining more body fat on high-fat diets.

Interactions

MTNR1B rs10830963 interacts with other type 2 diabetes risk loci. Carriers of the G allele here who also carry the TCF7L2 rs7903146 risk allele (T) face compounded diabetes risk through independent but converging pathways — MTNR1B impairing insulin secretion timing, TCF7L2 impairing beta cell development and incretin signaling. Both SNPs are independently actionable: meal timing for MTNR1B, dietary fat moderation for TCF7L2.

The CLOCK gene variant rs1801260 influences chronotype (morning vs. evening preference), which in turn affects when melatonin rises and falls. An evening chronotype combined with the MTNR1B G allele could extend the overlap between elevated melatonin and late eating, though direct evidence for this specific gene-gene interaction remains limited.

MTCH2 (Mitochondrial Carrier Homolog 2) encodes a protein embedded in the outer mitochondrial membrane that regulates how your cells burn fat versus store it. The rs10838738 variant is an intronic SNP that functions as a cis-eQTL¹¹ cis-eQTL
a genetic variant that affects the expression level of a nearby gene, increasing MTCH2 mRNA expression in adipose tissue. Higher MTCH2 levels tip the balance toward fat storage over fat oxidation.

The Mechanism

MTCH2 sits on the outer mitochondrial membrane where it directly regulates CPT1²² CPT1
carnitine palmitoyltransferase 1, the rate-limiting enzyme for fatty acid entry into mitochondria for oxidation. When MTCH2 is abundant, it increases CPT1 sensitivity to malonyl-CoA³³ malonyl-CoA
a metabolic intermediate that inhibits fat oxidation when energy is plentiful, effectively putting a brake on fatty acid oxidation. Conversely, when MTCH2 is reduced, CPT1 becomes less sensitive to malonyl-CoA inhibition, allowing increased fat burning.

The G allele at rs10838738 is in near-complete linkage disequilibrium (R² = 0.997) with rs1064608, which encodes a p.Pro290Ala⁴⁴ p.Pro290Ala
a proline-to-alanine substitution affecting protein function missense change in MTCH2. The G allele is associated with higher MTCH2 expression, leading to:

• Enhanced CPT1 malonyl-CoA sensitivity (reduced fat oxidation)
• Increased adipogenesis and lipid accumulation
• Reduced mitochondrial oxidative phosphorylation efficiency
• Lower overall energy expenditure

Mice lacking MTCH2 in muscle show increased whole-body energy utilization and protection from diet-induced obesity⁵⁵ increased whole-body energy utilization and protection from diet-induced obesity
Buzaglo-Azriel et al. Loss of Muscle MTCH2 Increases Whole-Body Energy Utilization and Protects from Diet-Induced Obesity. Cell Reports, 2016, demonstrating that MTCH2 reduction is metabolically favorable for weight management.

The Evidence

The GIANT consortium⁶⁶ GIANT consortium
Willer et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nature Genetics, 2009 meta-analysis of over 32,000 individuals identified MTCH2 as one of six genome-wide significant BMI loci (P = 1.9 x 10^-11). The per-allele BMI increase is approximately 0.07 kg/m^2.

A landmark study on opposing effects⁷⁷ landmark study on opposing effects
Fischer et al. Opposing effects of genetic variation in MTCH2 for obesity versus heart failure. Human Molecular Genetics, 2023 showed that while higher MTCH2 expression increases obesity risk, reduced MTCH2 expression may be disadvantageous during heart failure, where impaired glucose oxidation and increased lactate accumulation become problematic.

Recent work in adipogenesis⁸⁸ adipogenesis
Stein et al. MTCH2 controls energy demand and expenditure to fuel anabolism during adipogenesis. EMBO Journal, 2025 demonstrated that MTCH2 is essential for the energy shift from catabolism to anabolism during fat cell differentiation, controlling both energy demand and expenditure during this process.

Practical Actions

Because MTCH2 directly affects mitochondrial fat oxidation through CPT1 regulation, interventions that support mitochondrial function and fatty acid metabolism are particularly relevant for G allele carriers. Supporting the mitochondrial electron transport chain and facilitating fatty acid entry into mitochondria can help compensate for the variant's effect.

Interactions

MTCH2 rs10838738 contributes to polygenic obesity risk alongside FTO rs9939609, MC4R rs17782313, KCTD15 rs29941, and ETV5 rs7647305. The MTCH2 mechanism is unique among these — it directly affects mitochondrial fat oxidation rather than appetite regulation (MC4R, ETV5) or adipogenesis signaling (KCTD15). This makes it mechanistically complementary: an individual carrying risk alleles at both MTCH2 (reduced fat oxidation) and KCTD15 (enhanced adipogenesis) would face a compound effect on fat accumulation through two independent pathways.

Most people have never heard of piRNAs¹¹ piRNAs
PIWI-interacting RNAs: small non-coding RNA molecules, 24–31 nucleotides long, that form complexes with PIWI proteins to silence transposable elements and protect genome integrity in germ cells. Yet the protein that guides these tiny sentinels — PIWIL1, encoded on chromosome 12q24.33 — may influence a woman's lifetime risk of epithelial ovarian cancer (EOC). A 2023 three-center case-control study in southern China found that the rs10848087 AA genotype in PIWIL1 was associated with a roughly 5.7-fold increase in EOC risk compared with the common GG genotype. While the evidence is currently limited to a single study in one ancestry group, the biological plausibility is strong and the finding warrants attention.

The Mechanism

PIWIL1 belongs to the Piwi/Argonaute superfamily²² Piwi/Argonaute superfamily
A broad family of RNA-guided proteins that use small RNA molecules as molecular GPS to silence target genes. PIWIL1 is the human ortholog of the Drosophila Piwi protein, originally named for its role in stem cell renewal in the fly germline. In normal ovarian and germ cells, PIWIL1 loads piRNAs and directs the silencing of transposable elements³³ transposable elements
Mobile DNA sequences (transposons) that can copy-and-paste themselves throughout the genome; uncontrolled transposon activity causes double-strand DNA breaks and genomic rearrangements via transcriptional suppression and post-transcriptional cleavage. When this guardian function is impaired, transposon-driven genomic instability can accumulate in somatic and germ cells.

The rs10848087 variant is a synonymous SNP⁴⁴ synonymous SNP
A nucleotide change that does not alter the amino acid sequence — here, both CTG and CTA encode leucine at position 376 of the 861-amino-acid PIWIL1 protein (c.1128G>A, Leu376Leu). Synonymous variants can still affect biology through altered codon usage⁵⁵ codon usage
Different synonymous codons are decoded at different speeds; rare codons can slow translation, affecting protein folding and function, mRNA stability, or splicing regulation. The authors of the 2023 study suggested the variant may alter PIWIL1 expression levels or create a cryptic splicing signal that affects normal PIWI domain function in ovarian somatic cells. The precise molecular mechanism linking this specific synonymous change to EOC susceptibility has not yet been experimentally characterized.

The Evidence

The primary evidence comes from a three-center case-control study⁶⁶ three-center case-control study
Liu et al. 2023, BMC Cancer, 288 EOC cases and 361 age-matched healthy controls from three hospitals in southern China. Five functional SNPs across the PIWIL1 gene were genotyped. The rs10848087 AA genotype was rare in controls (3/350, ~0.9%) but substantially more common in cases (12/288, ~4.7%), yielding an adjusted OR of 5.654 (95% CI 1.562–20.464, p=0.0083) after controlling for age, menopausal status, and reproductive history. The three-genotype comparison also showed a significant additive trend.

AA genotype carriers in the case group were enriched across multiple pathological subgroups: metastatic vs. non-metastatic disease, FIGO stages I and III, both low and high pathological grade, and tumor numbers greater or less than 3. The broad distribution across disease characteristics suggests the variant acts on susceptibility rather than on a specific histological subtype.

Contextualizing the molecular associations: a 2014 study found PIWIL1 protein overexpression specifically in malignant EOC⁷⁷ PIWIL1 protein overexpression specifically in malignant EOC
Lim et al. 2014, PLoS One; PIWIL1 and MAEL significantly elevated in cancer vs. benign and normal ovarian tissue, and a 2020 comprehensive analysis of the piRNA pathway in ovarian cancer found that PIWIL1 expression levels correlated with survival outcomes⁸⁸ PIWIL1 expression levels correlated with survival outcomes
Lee et al. 2020, Cancers; disparate piRNA pathway gene expression linked to progression-free, post-progression, and overall survival. Across multiple tumor types, PIWIL1 overexpression associates with advanced stage and lymph node metastasis.

Important limitations: this is a single study in an East Asian population, sample sizes are modest (especially for the rare AA genotype), and results have not been independently replicated. The evidence level is therefore emerging. Population frequencies suggest AA homozygosity is rare globally (~3.4%) and particularly rare in East Asian ancestries (~1.3%), meaning this finding applies to a small fraction of women.

Practical Implications

The AA genotype is rare, but when present in women with other EOC risk factors (family history, BRCA status, nulliparity, endometriosis, older age at first pregnancy), it may augment cumulative risk. Current evidence is insufficient to recommend altered screening protocols based on rs10848087 alone. However, women who are AA homozygous and have additional EOC risk factors may benefit from discussing the variant with a gynecologic oncologist and ensuring they undergo routine recommended ovarian cancer risk assessment.

The heterozygous GA genotype does not appear to carry the same risk signal — in the primary study, GA was not independently associated with EOC susceptibility, and the effect appears to follow a recessive pattern (AA vs. GG/GA).

Interactions

The primary study also found rs7957349 G>C (also in PIWIL1) independently associated with EOC risk (CC genotype, OR 2.984) and rs10773771 C>T to be protective (CC genotype, OR 0.573). Haplotype analysis indicated the GTG haplotype (across rs10848087, rs10773771, rs7957349) was associated with decreased EOC risk. These PIWIL1 variants appear to modulate EOC susceptibility through different mechanisms and may interact cumulatively.

A proposed compound consideration: women who carry rs10848087 AA alongside the rs7957349 CC risk genotype would have two independent PIWIL1-region risk signals converging; combined risk from this haplotype configuration has not been separately quantified but warrants attention in future studies.

Adiponectin is one of the most abundant hormones secreted by fat tissue, with a critical and counterintuitive property: its levels fall as body fat increases, precisely when the body needs its metabolic protection most. Low circulating adiponectin is a consistent predictor of insulin resistance, type 2 diabetes, dyslipidaemia, and cardiovascular disease¹¹ Low circulating adiponectin is a consistent predictor of insulin resistance, type 2 diabetes, dyslipidaemia, and cardiovascular disease
Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439–451. Adiponectin acts exclusively through two transmembrane receptors: ADIPOR1, which dominates in skeletal muscle, and ADIPOR2, which dominates in the liver. rs10848554 is an intronic variant in the ADIPOR2 gene — it does not change the receptor's amino acid sequence, but it co-segregates with other ADIPOR2 variants that alter receptor expression and cardiovascular risk, tagging a shared haplotype across this locus.

The Mechanism

When adiponectin binds ADIPOR2 in hepatocytes, two downstream signaling arms activate: the AMPK pathway²² AMPK pathway
AMP-activated protein kinase — a master energy sensor that shifts the liver from fat synthesis to fat oxidation, suppresses gluconeogenesis, and improves glucose uptake and the PPARα pathway³³ PPARα pathway
Peroxisome proliferator-activated receptor alpha — a nuclear receptor that drives transcription of hepatic fatty acid oxidation genes; ADIPOR2 is its primary activator in liver. Together these pathways reduce hepatic triglyceride accumulation, improve LDL clearance, lower fasting glucose, and suppress inflammatory lipid species. When ADIPOR2 expression is reduced — as happens in visceral obesity — PPARα and AMPK signaling in the liver falls, creating rising triglycerides, impaired LDL clearance, and growing insulin resistance⁴⁴ When ADIPOR2 expression is reduced — as happens in visceral obesity — PPARα and AMPK signaling in the liver falls, creating rising triglycerides, impaired LDL clearance, and growing insulin resistance
Demonstrated in both human liver biopsies from obese subjects and mouse models of visceral adiposity. The C allele at rs10848554 tags a haplotype at the ADIPOR2 locus associated with this impaired signaling state.

The Evidence

The primary evidence for rs10848554 comes from the Finnish Diabetes Prevention Study (DPS)⁵⁵ Finnish Diabetes Prevention Study (DPS)
A landmark randomized lifestyle intervention trial enrolling individuals with impaired glucose tolerance; the DPS genotyping sub-study examined 484 participants for ADIPOR2 variants and followed them for a median of 10.2 years for cardiovascular events and diabetes progression. Eight ADIPOR2 SNPs were analyzed; rs10848554 was one of four that showed initial association with cardiovascular disease risk, alongside rs11061937, rs1058322, and rs16928751. These four variants were entered into a joint multi-SNP model, in which rs11061937 (p = 0.014) and rs1058322 (p = 0.020) retained independent significance. rs10848554 and rs16928751 did not maintain independent significance after adjusting for the other two variants — indicating that rs10848554 tags overlapping genetic information captured by the stronger signals, consistent with its role as part of an extended ADIPOR2 haplotype.

The broader biological context is well-supported. Synthetic AdipoR agonists that activate both ADIPOR1 and ADIPOR2 reduce insulin resistance, improve glucose tolerance, and extend lifespan in obese diabetic mice⁶⁶ Synthetic AdipoR agonists that activate both ADIPOR1 and ADIPOR2 reduce insulin resistance, improve glucose tolerance, and extend lifespan in obese diabetic mice
Okada-Iwabu et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature, 2013, validating the receptor pathway as causally relevant to metabolic and cardiovascular outcomes. Hepatic ADIPOR2 is specifically downregulated in visceral obesity while ADIPOR1 expression is preserved⁷⁷ while ADIPOR1 expression is preserved
Bjursell M et al. Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes, 2007, making it a vulnerable node where genetic and environmental risk factors converge.

Practical Actions

The actionable strategy for ADIPOR2 haplotype variants is to raise circulating adiponectin concentration — increasing ligand availability to compensate for any receptor-level impairment — while independently supporting the AMPK and PPARα pathways through dietary fat composition. Omega-3 fatty acids (EPA and DHA) consistently raise serum adiponectin in intervention studies and support hepatic fatty acid oxidation. Replacing saturated fat with polyunsaturated fat raises adiponectin by 10–15% in controlled dietary trials. Given the Finnish DPS finding linking this variant cluster to cardiovascular outcomes in at-risk individuals, fasting cardiometabolic monitoring is appropriate for C allele carriers, particularly those with impaired fasting glucose, elevated triglycerides, or a family history of cardiovascular disease.

Interactions

rs10848554 was genotyped alongside rs11061937, rs1058322, and rs16928751 in the Finnish DPS, all four showing nominal CVD association. Because rs10848554's association did not survive multi-variant adjustment, it most likely tags the same functional haplotype as the two independently significant variants — rs11061937 and rs1058322 — rather than an independent signal. Individuals carrying C alleles at multiple ADIPOR2 loci (rs10848554, rs11061937, rs1058322) likely carry the full ADIPOR2 risk haplotype, with compounded reduction in hepatic adiponectin responsiveness. For individuals who also carry lipid metabolism risk variants (e.g., in APOE, LDLR, or FADS genes), the combination of impaired ADIPOR2 signaling with intrinsically dysregulated lipid handling may represent a more substantial cardiometabolic risk profile than either pathway alone.

The FTO (fat mass and obesity-associated) gene contains one of the most replicated loci in human obesity genetics. While the primary signal — tagged by rs9939609¹¹ rs9939609
The most studied FTO variant; explained in the Energy & Weight category — sits in a regulatory cluster in intron 1 that controls IRX3/IRX5 expression in preadipocytes, the FTO locus harbors multiple distinct linkage disequilibrium²² linkage disequilibrium
LD: the tendency of nearby genetic variants to be inherited together. Variants in the same LD block are correlated; independent signals are in different LD blocks blocks spanning the gene. rs10852521 is an intronic FTO variant that tags a separate LD block with its own — though overlapping — association with body mass index and related adiposity traits.

The Mechanism

rs10852521 is located in intron 1 of FTO at chromosome 16:53,771,053 (GRCh38). Like other FTO intron 1 variants, it is not itself a coding mutation — it does not change any amino acid sequence. Instead, intronic FTO variants influence FTO primary transcript abundance³³ FTO primary transcript abundance
Risk alleles increase FTO mRNA levels, shifting the m6A demethylase toward higher activity. FTO encodes an N6-methyladenosine (m6A) RNA demethylase⁴⁴ N6-methyladenosine (m6A) RNA demethylase
m6A is the most abundant chemical modification on messenger RNA; FTO removes it, altering mRNA processing, stability, and translation of target genes. Through this m6A eraser activity, FTO regulates ghrelin mRNA stability — increased FTO expression raises circulating ghrelin, the principal hunger hormone, and simultaneously promotes preadipocyte differentiation toward energy-storing white adipocytes rather than thermogenic beige adipocytes. Higher FTO transcript levels thus tilt energy balance toward fat accumulation through two reinforcing routes: increased appetite signaling and reduced thermogenesis.

The Evidence

The clearest evidence for rs10852521 comes from a multiethnic analysis of FTO variants⁵⁵ multiethnic analysis of FTO variants
Wing et al. 2011, Insulin Resistance Atherosclerosis Study (IRAS) Family Study cohort examining 26 FTO SNPs across Hispanic American, African American, and non-Hispanic White participants. In Hispanic Americans (n=373), rs10852521 showed the most significant per-SNP BMI association after Bonferroni correction (p=5.2×10⁻⁴). The association was nominally significant in African Americans (p=4.4×10⁻³) and non-Hispanic Whites (p=0.048), following the same directional pattern. Notably, the variant falls in a different LD block from rs9939609 in African-ancestry populations — meaning it tags partially independent genetic variation, not just the same causal alleles in disguise.

The broader FTO locus biology reinforces this interpretation. Physical activity attenuates FTO-driven obesity risk⁶⁶ Physical activity attenuates FTO-driven obesity risk
Meta-analysis of 218,166 adults: active individuals show 27% lower FTO allele effect than sedentary individuals consistently across FTO variants, reflecting the gene-environment interaction at the level of the locus rather than any single SNP. Exercise training studies find that FTO C-allele carriers lose approximately three times more fat mass⁷⁷ lose approximately three times more fat mass
Rankinen et al. 2010, HERITAGE Family Study, 20-week supervised endurance training than T/T homozygotes in response to structured endurance training — an effect accounting for roughly 2% of the variance in fat mass change with exercise.

The evidence level for rs10852521 specifically is rated moderate: the association is replicated across ethnicities and consistent with FTO locus biology, but effect sizes for this specific variant are less precisely estimated than for the primary rs9939609 / rs1421085 cluster, and the variant is not yet catalogued in ClinVar or GWAS Catalog as an independent signal.

Practical Actions

The key finding from exercise studies — that C-allele carriers show disproportionately larger fat mass reductions from aerobic training — is directly actionable. This variant suggests that structured endurance training is particularly effective at mobilizing FTO-associated fat accumulation. The mechanism may involve compensatory upregulation of thermogenic pathways that counteract the intronic FTO regulatory signal.

Diet composition also matters for FTO carriers: higher-protein diets (25% of calories) reduce food cravings and improve satiety signaling in FTO risk allele carriers, likely compensating for reduced GLP-1 and peptide YY responses that contribute to impaired fullness perception.

Interactions

rs10852521 is in partial linkage disequilibrium with the primary FTO obesity signals (rs9939609, rs1421085, rs8050136) in European-ancestry populations, but the LD structure differs in African-ancestry populations — making rs10852521 a more informative independent tag SNP in those ancestral groups. Users who also carry the rs9939609 A allele (the primary FTO risk variant) face compounded FTO pathway burden, as both variants increase FTO transcript levels through potentially distinct regulatory mechanisms in the intron 1 region.

Tucked within the introns of PLCE1 on chromosome 10, rs10882398 marks a variant that influences blood pressure across the lifespan and reaches its most dramatic clinical expression during pregnancy. PLCE1 (phospholipase C epsilon 1) encodes an enzyme that hydrolyzes membrane phospholipids to generate second messengers — primarily IP3 (inositol trisphosphate) and diacylglycerol¹¹ IP3 (inositol trisphosphate) and diacylglycerol
IP3 triggers calcium release from intracellular stores; DAG activates protein kinase C — together they regulate vascular smooth muscle tone, podocyte survival, and endothelial function. The A allele at this locus nudges systolic blood pressure upward, amplifies risk for preeclampsia, and — through the kidney's filtration cells — leaves carriers less able to tolerate the haemodynamic demands of hypertension.

The Mechanism

PLCE1 is expressed in two cell types that directly regulate vascular pressure and renal filtration: glomerular podocytes²² glomerular podocytes
the specialized foot-process cells that form the kidney's filtration barrier; podocyte loss is a hallmark of hypertensive kidney disease and arteriolar smooth muscle cells in the kidney glomerulus. In endothelial cells it operates downstream of Rap-1 signaling to elevate intracellular calcium via the IP3 pathway, driving prostacyclin (PGI2) synthesis — an endogenous vasodilatory and antithrombotic mediator.

When PLCE1 function is compromised, two pathways toward elevated pressure are implicated. First, impaired endothelial PLCε-to-calcium signaling reduces PGI2 output, tipping the prostanoid balance toward vasoconstriction. Second, the kidney's pressure-buffering capacity diminishes: in mice, PLCE1 deficiency produces no renal phenotype at normal blood pressure but causes 20-fold increased albuminuria, glomerulosclerosis, and podocyte loss when hypertension is induced³³ 20-fold increased albuminuria, glomerulosclerosis, and podocyte loss when hypertension is induced, consistent with a genotype that tolerates normal pressures but amplifies injury under stress. During pregnancy, the haemodynamic demands of placentation — which normally require spiral artery remodelling and careful blood pressure management — may expose this vulnerability acutely.

rs10882398 is an intronic variant and does not change the PLCE1 protein sequence. It is a tag SNP marking a regulatory haplotype that modifies PLCE1 expression levels or splicing in relevant tissues. The exact molecular mechanism by which this haplotype reduces PLCE1 function has not been characterized at the biochemical level.

The Evidence

The blood pressure association is genome-wide significant and replicated across hundreds of thousands of participants. The GWAS Catalog records an A-allele association with systolic blood pressure at p=9×10⁻²³ (beta=0.019 mmHg per A allele), and with preeclampsia/pregnancy-induced hypertension combined at OR=1.11 (95% CI 1.08–1.14; p=2×10⁻¹³).

Tyrmi et al., JAMA Cardiology 2023⁴⁴ Tyrmi et al., JAMA Cardiology 2023 conducted the largest preeclampsia GWAS to date, combining 16,743 women with preeclampsia from the Finnish FINNPEC and FinnGen cohorts, the Estonian Biobank, and the international InterPregGen consortium. Among 19 genome-wide significant associations — 13 of them novel — PLCE1 was identified as one of seven loci carrying genes previously known to regulate blood pressure (alongside NPPA, NPR3, TNS2, FURIN, RGL3, and PREX1), reinforcing the concept that preeclampsia shares genetic architecture with essential hypertension.

Changalidis et al., Genes 2022⁵⁵ Changalidis et al., Genes 2022 confirmed the rs10882398 signal independently: a meta-analysis of FinnGen and UK Biobank GWAS summary statistics across 24 pregnancy complications identified rs10882398 in PLCE1 as one of three loci reaching genome-wide significance (p=8.9×10⁻⁹) for pregnancy hypertension.

The mechanistic evidence for PLCE1 in blood pressure comes from Atchison et al., American Journal of Physiology Renal Physiology 2020⁶⁶ Atchison et al., American Journal of Physiology Renal Physiology 2020: PLCE1-null mice develop severe glomerulosclerosis under experimentally induced hypertension, with albuminuria 20-fold above wild-type controls, establishing a clear gene-dose relationship between PLCE1 status and pressure-mediated kidney injury.

Practical Actions

For A-allele carriers, the clinically actionable implications run in two directions: blood pressure control is more protective than average because the PLCE1-deficient kidney is disproportionately sensitive to elevated pressure; and pregnancy represents a period of amplified cardiovascular risk requiring proactive monitoring.

Dietary sodium restriction achieves measurably larger blood pressure reductions in individuals with genetically elevated pressure set-points at GWAS-identified loci. At the A allele's beta of ~0.02 mmHg per copy, homozygous carriers accumulate a meaningful additive genetic pressure contribution that compounds with modifiable risk factors like sodium, obesity, and sleep-disordered breathing.

Monitoring with 24-hour ambulatory blood pressure measurement (ABPM) rather than clinic readings captures early nocturnal hypertension — the pattern most predictive of end-organ damage in genetically elevated pressure phenotypes. For women planning pregnancy, early-trimester blood pressure baseline and low-dose aspirin prophylaxis (75–150 mg daily from 12 weeks) represent evidence-based preeclampsia risk reduction strategies endorsed by ACOG and NICE for elevated-risk individuals.

Interactions

PLCE1 rs10882398 shares pathway biology with rs932764 (PLCE1 hypertension susceptibility variant associated with antihypertensive drug response differences between racial groups; PMID:31327267) — both are PLCE1 intronic variants, and their LD relationship and combined effect on PLCE1 expression have not been fully characterized.

The blood pressure associations at rs10882398 overlap with the FGF5 and RGL3 blood-pressure loci co-identified in the same preeclampsia GWAS, suggesting that the genetic architecture of pregnancy hypertension mirrors essential hypertension — multiple additive loci, each contributing a small but real pressure increment, with the cumulative burden materializing clinically during the haemodynamic stress of pregnancy.

Telomeres — the repetitive DNA caps that protect chromosome ends — shorten with every cell division, acting as a biological clock that marks cellular age. The gene TERC encodes the RNA template that the telomerase enzyme uses to rebuild these caps, and the chromosomal region 3q26.2 harboring TERC contains some of the strongest genetic determinants of telomere length discovered through population genetics.

rs10936599 is a regulatory variant near TERC that emerged as the single most significant predictor of leukocyte telomere length in the landmark 2013 genome-wide meta-analysis by Codd and colleagues. Its biology illustrates a striking paradox at the heart of telomere science: the allele that maintains longer telomeres also increases the risk of certain cancers, while the allele linked to shorter telomeres — and accelerated cellular aging — appears to reduce cancer susceptibility.

The Mechanism

rs10936599 sits approximately near the 5'UTR region of TERC in an area that influences how much TERC RNA the cell produces or how stable that RNA is. TERC does not encode a protein — it is the RNA template that TERT (the protein catalytic component) uses to add the TTAGGG repeat sequence back to shortening telomere ends.

The C allele (major, ~75% frequency) is associated with higher TERC mRNA levels and longer telomeres — approximately 117 base pairs more per allele¹¹ 117 base pairs more per allele
from the ENGAGE consortium data in Codd et al. 2013. The T allele (minor, ~25% frequency) appears to reduce TERC expression or activity, resulting in less efficient telomere rebuilding and telomeres that are measurably shorter over a lifetime.

The paradox arises because longer telomeres suppress cellular senescence — the process that normally kills precancerous cells before they can proliferate. Cells with genetically longer telomeres can divide more times before entering senescence, which is protective against age-related organ failure but removes one of the body's natural cancer checkpoints. This is why the C allele (longer telomere) appears in GWAS findings for colorectal cancer, glioma, lung cancer, and multiple sclerosis susceptibility, while the T allele (shorter telomere) increases risk for cardiovascular disease and COPD — diseases driven by premature cellular exhaustion rather than unchecked proliferation.

The Evidence

The definitive characterization of rs10936599 came from a genome-wide meta-analysis of 37,684 individuals with replication in 10,739 more²² genome-wide meta-analysis of 37,684 individuals with replication in 10,739 more
Codd V et al. Identification of seven loci affecting mean telomere length. Nat Genet 2013. The T allele was the strongest single-SNP predictor of shorter telomeres in the entire genome (beta = −0.097, P = 2.54×10⁻³¹), explaining 0.36% of variance in leukocyte telomere length — equivalent to approximately 3.9 years of age-related telomere attrition per T allele.

The same meta-analysis identified rs10936599 as part of a seven-SNP genetic risk score (GRS) for telomere length — a tool now widely used in Mendelian randomization studies to tease apart the causal effects of telomere length from confounders. rs10936599 contributes the largest single weight in this GRS, making it the anchor SNP for genetically determined telomere length in population genetics research.

The earlier 2010 GWAS in 12,409 individuals³³ 2010 GWAS in 12,409 individuals
Codd V et al. Common variants near TERC are associated with mean telomere length. Nat Genet 2010 first established the TERC 3q26 locus as the top genetic determinant of leukocyte telomere length, and rs10936599 tags the strongest signal within this locus.

For cardiovascular health, a prospective study of acute heart failure patients⁴⁴ prospective study of acute heart failure patients
Chen et al. Frontiers in Endocrinology 2021 found that rs10936599 genotype was an independent predictor of 18-month mortality. In the dominant model (CC+CT vs TT), mutant allele carriers had HR 2.84 (95% CI 1.48–5.44, P = 0.001) for death — a clinically significant prognostic effect in patients with established heart disease.

A case-control study in Chinese Han individuals⁵⁵ case-control study in Chinese Han individuals
Li et al. Scientific Reports 2017 found that the C allele at rs10936599 was associated with increased ischemic stroke risk (OR = 1.26, 95% CI 1.00–1.58, P = 0.049). This finding, where the longer-telomere C allele increases stroke risk, reflects the complex pleiotropic effects of telomere length on vascular biology that vary by context, age, and disease stage.

The Longevity-Aging Framing

In the longevity-aging context, the T allele is the primary concern: it reduces telomere maintenance capacity, accelerating the rate at which cells accumulate telomere damage and enter senescence. Each T allele is equivalent to approximately 3.9 years of extra biological aging at the telomere level. TT homozygotes — carrying two T alleles — have telomeres genetically comparable to someone nearly 8 years older.

Critically, the T allele interacts with lifestyle factors that independently shorten telomeres: smoking, chronic inflammation, psychological stress, and oxidative load. For carriers of the T allele, these environmental insults deplete an already smaller telomere reserve.

The C allele (normal for longevity purposes) does carry its own complex biology — the longer-telomere state mildly increases risk for some cancers by reducing cellular senescence as a tumor-suppressive mechanism. This is worth knowing but is a very different clinical concern from accelerated aging.

Interactions

rs10936599 is part of the TERC 3q26.2 locus that also harbors rs12696304 and rs16847897, two other variants associated with telomere length. These SNPs are not in tight linkage disequilibrium and may tag partially independent regulatory effects on TERC expression. Individuals carrying the T allele at rs10936599 alongside risk alleles at rs12696304 (G) or rs16847897 (C) may have compounded reduction in telomere maintenance from the TERC locus.

At the pathway level, rs10936599 interacts with TERT rs2736100 (the catalytic protein component of telomerase). Both TERC and TERT must function adequately for telomere maintenance; individuals with reduced function at both loci face the most pronounced telomere attrition.

rs10936599 is included in the standard seven-SNP Mendelian randomization genetic instrument for telomere length alongside rs2736100, rs7675998, rs9420907, rs8105767, rs755017, and rs11125529 — reflecting its role as the dominant genetic determinant of leukocyte telomere length in the genome.

Your liver is constantly converting cholesterol into bile acids — the detergent-like molecules that emulsify dietary fat and exit the body via the gut. The enzyme that sets the pace for this entire process is cholesterol 7α-hydroxylase¹¹ cholesterol 7α-hydroxylase
CYP7A1 catalyzes the first and rate-limiting step of the classic bile acid synthesis pathway, converting cholesterol to 7α-hydroxycholesterol, encoded by the CYP7A1 gene. The faster this enzyme works, the more cholesterol gets converted to bile acids and cleared, and the lower your LDL tends to be. Variants upstream of CYP7A1 — including rs1125226 — help define haplotypes that collectively tune how much bile acid your liver produces.

The Mechanism

CYP7A1 sits in hepatocyte endoplasmic reticulum membranes and governs the neutral (classic) bile acid pathway²² neutral (classic) bile acid pathway
The classic pathway accounts for ~75% of all bile acid production in humans; the alternative acidic pathway handles the remainder. Its expression is regulated by a network of nuclear receptors: LXRα activates CYP7A1 transcription in response to excess hepatic cholesterol, while FXR (activated by returning bile acids from the gut) represses it as a feedback brake. rs1125226 sits approximately 6.8 kb upstream of the CYP7A1 transcription start site — within the extended promoter/regulatory region — and is a haplotype-tagging SNP for this gene. It was characterised as part of a systematic mapping of CYP7A1's linkage disequilibrium blocks³³ linkage disequilibrium blocks
regions of the genome inherited together more often than chance alone across five population groups.

The rs1125226 A allele co-segregates with specific CYP7A1 promoter haplotypes, of which the well-studied rs3808607 variant is the primary functional site. In hepatocyte assays, the rs3808607 G allele (which travels with certain rs1125226 haplotypes) drives higher CYP7A1 mRNA expression⁴⁴ higher CYP7A1 mRNA expression
Inamine et al. 2013: the G-allele promoter induced significantly higher CYP7A1 expression under both normal and cholestatic conditions than the T allele. The combined two-SNP regulatory model spanning promoter and enhancer spans more than two orders of magnitude in hepatic CYP7A1 expression⁵⁵ two orders of magnitude in hepatic CYP7A1 expression
Wang et al. 2018: only the two-SNP model, not either SNP alone, significantly associated with LDL levels, CAD risk, statin response, and T2D.

The Evidence

A 2023 meta-analysis by Lim et al.⁶⁶ Lim et al.
Lim MYC et al. A meta-analysis of the pooled impact of CYP7A1 single nucleotide polymorphisms on serum lipid responses to statins. Front Genet, 2023 pooled statin-response data and found that CYP7A1 variant carriers had significantly smaller reductions in total cholesterol (WMD −0.17 mmol/L, 95% CI −0.29 to −0.06) and LDL (WMD −0.16 mmol/L, 95% CI −0.26 to −0.05) compared to non-carriers.

Dietary studies add a complementary picture. Wang et al. 2017⁷⁷ Wang et al. 2017
Wang Y et al. Barley β-glucan reduces blood cholesterol levels via interrupting bile acid metabolism. Br J Nutr, 2017 showed that high-molecular-weight barley β-glucan increased bile acid synthesis in all participants, but the effect was "more pronounced" in homozygous G carriers at rs3808607 — the individuals whose CYP7A1 promoter appears most responsive. This genotype-by-diet interaction suggests that dietary cholesterol-lowering strategies targeting bile acid excretion may be especially effective for people whose CYP7A1 is already tuned high.

The earlier Hubacek & Bobkova review⁸⁸ Hubacek & Bobkova review
Hubacek JA, Bobkova D. Role of cholesterol 7alpha-hydroxylase (CYP7A1) in nutrigenetics and pharmacogenetics of cholesterol lowering. Mol Diagn Ther, 2006 summarised the opposing direction of effect: −204CC homozygotes (at rs3808607) showed the greatest cholesterol reduction from dietary changes, while the −204AA homozygotes responded slightly better to statin therapy. This divergence likely reflects the enzyme's feedback relationship with statins — statins upregulate CYP7A1 as a compensatory mechanism, and individuals with higher baseline CYP7A1 activity may have a ceiling effect.

Direct evidence for rs1125226 alone is limited. The Fu et al. 2011 study⁹⁹ Fu et al. 2011 study
Fu L et al. CYP7A1 genotypes and haplotypes associated with hypertension in an obese Han Chinese population. Hypertens Res, 2011 found no significant independent effect of rs1125226 genotype on hypertension susceptibility, though haplotypes combining rs3808607 and rs1125226 alleles showed significant differences. rs1125226 is best interpreted as a haplotype marker that defines which CYP7A1 regulatory environment you carry, rather than as an independent functional variant.

Practical Actions

For A allele carriers whose haplotype co-occurs with lower CYP7A1 activity signatures, a practical strategy is to emphasise dietary routes that maximise bile acid excretion. Soluble fibre from oats, barley (β-glucan), psyllium, and legumes binds bile acids in the gut and forces the liver to convert more cholesterol to replace them — effectively using diet to compensate for a genetically slower enzymatic throttle. LDL response to statin therapy should be monitored, as meta-analytic data suggest carriers may achieve somewhat smaller LDL reductions at standard doses.

For CC homozygotes, the complementary picture holds: dietary interventions targeting bile acid excretion are likely to be especially responsive, while statin response may be modestly blunted relative to the population average.

Interactions

rs1125226 is a haplotype partner to rs3808607, the CYP7A1 A-204C promoter variant. Their combined haplotype structure is the primary lens through which CYP7A1 regulatory variation should be interpreted — no single SNP in this region tells the whole story. Additionally, CYP7A1 operates at the top of the bile acid synthesis cascade; variants in downstream genes (CYP8B1, BSEP/ABCB11, FXR/NR1H4) and in the cholesterol clearance pathway (APOE rs429358, LDLR) can modify the net effect of CYP7A1 haplotype variation on plasma LDL.

The FCRL3¹¹ FCRL3
Fc receptor-like 3; expressed at high levels on B cells and regulatory T cells, where it modulates activation thresholds and autoantibody production through immunoreceptor tyrosine-based inhibitory and activation motifs (ITIMs and ITAMs) gene sits on chromosome 1q23, a region densely populated with immune receptor genes. rs11264799 lies approximately 59 bp from the well-studied rs7528684 promoter variant, placing it squarely in the upstream regulatory landscape of FCRL3. The variant itself does not change the FCRL3 protein — it is classified as an upstream transcript variant — but it exerts a measurable influence on how much FCRL3 is produced in immune cells.

FCRL3 is on the minus strand of chromosome 1; the alleles reported in genome files (C and T) are plus-strand notation. The C allele is the GRCh38 reference and the more common allele globally (~73%); the T allele is the minor variant (~27%) that carries the eQTL signal.

The Mechanism

rs11264799 has been identified as a strong expression quantitative trait locus (eQTL)²² strong expression quantitative trait locus (eQTL)
eQTLs are genetic variants that influence the amount of RNA or protein produced by a nearby gene; they act as natural experiments showing how subtle regulatory changes alter gene dosage in human tissues for FCRL3. In B cells and regulatory T cells, higher FCRL3 expression alters the balance between activation and inhibition: more surface FCRL3 can either amplify or dampen B cell receptor signals depending on the cellular context. The T allele's eQTL effect on FCRL3 expression in lymphoid tissue explains why it has been repeatedly captured in genetic studies of conditions where B cell tolerance is central — IgA nephropathy, autoimmune thyroid disease, and inflammatory arthritis — even though the individual SNP associations are smaller and less consistent than those seen for the closely linked rs7528684 promoter variant.

The T allele is in linkage disequilibrium with rs6427389, a variant that reached genome-wide significance (OR=1.132, P=8.18×10⁻⁹) in a large IgAN GWAS meta-analysis; the authors noted that rs11264799 was the likely functional mediator through its FCRL3 eQTL activity.

The Evidence

The clearest evidence for rs11264799 comes from IgA nephropathy, a condition in which autoantibodies against galactose-deficient IgA1 drive mesangial immune complex deposition and progressive kidney disease. A large Chinese case-control study of 1,750 IgAN patients and 2,500 controls³³ large Chinese case-control study of 1,750 IgAN patients and 2,500 controls
Zhong Z, Feng S, Shi D et al. Association of FCRL3 Gene Polymorphisms with IgA Nephropathy in a Chinese Han Population. DNA Cell Biol 39:154–162, 2020 found rs11264799 significantly associated with IgAN susceptibility after Bonferroni correction, with the T allele linked to altered FCRL3 expression. A subsequent genome-wide meta-analysis across Chinese and European IgAN cohorts⁴⁴ genome-wide meta-analysis across Chinese and European IgAN cohorts
Li M et al. Genome-Wide Meta-Analysis Identifies Three Novel Susceptibility Loci. J Am Soc Nephrol 31:2045–2057, 2020 confirmed the 1q23.1 FCRL3 locus at genome-wide significance, identifying rs11264799 as the key eQTL variant underlying the association signal.

In the broader autoimmune context, a meta-analysis of 34 case-control studies⁵⁵ meta-analysis of 34 case-control studies
Yang Y, Su X, Zhang K, Zhou R. Autoimmunity 46:547–558, 2013 found rs11264799 significantly associated with autoimmune diseases in mixed ethnic subgroups, though associations in individual European or Asian populations were not consistently replicated across diseases. Heterogeneity between studies — different LD structures, disease definitions, and population ancestries — explains why single-study results for this variant are frequently negative even when the eQTL signal at the locus is robust.

For rheumatoid arthritis, multiple sclerosis, and SLE individually, rs11264799 has not shown independent replication in European cohorts; the bulk of disease association evidence for FCRL3 in these conditions is carried by the closely linked rs7528684. The evidence base for rs11264799 specifically is therefore classified as emerging.

Practical Actions

The T allele at rs11264799 acts primarily through altered FCRL3 expression, placing this variant in the same functional context as rs7528684: conditions where B cell hyperactivity and impaired immune tolerance are central. The most directly supported disease link is IgA nephropathy; broader autoimmune connections remain plausible given the eQTL mechanism but are not independently confirmed for this variant.

For TT carriers, the most actionable step is awareness of early IgAN symptoms — particularly recurrent visible haematuria (blood in urine) following upper respiratory infections, which is the hallmark presentation — and periodic urinalysis to detect subclinical proteinuria or microhaematuria before kidney function is affected.

Interactions

rs11264799 is 59 bp from rs7528684 in the FCRL3 upstream region; both variants influence FCRL3 expression and are likely to be in partial linkage disequilibrium. The rs7528684 G allele has the stronger and better-replicated autoimmune association (RA, Graves' disease, Hashimoto's thyroiditis via NF-κB binding), while rs11264799 contributes an additional eQTL layer that may operate semi-independently. Carriers of risk alleles at both loci may have amplified FCRL3 dysregulation compared to carriers of either alone, though direct compound heterozygosity data are not yet published.